奥麦罗制药与诺和诺德达成21亿美元的药物许可协议

老虎资讯综合
Oct 15

周三, 奥麦罗制药 股价狂飙,截至发稿涨幅超150%。消息称奥麦罗制药与诺和诺德达成21亿美元的药物许可协议,涉及临床阶段Masp-3抑制剂Zaltenibart。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10